Research programme: theranostics - NuvOx Pharma

Drug Profile

Research programme: theranostics - NuvOx Pharma

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator NuvOx Pharma
  • Developer NuvOx Pharma; Stanford University
  • Class Anti-infectives; Anti-ischaemics; Antineoplastics; Eye disorder therapies; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers; Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Bacterial endocarditis; Breast cancer; Pancreatic cancer; Uveitis

Most Recent Events

  • 27 Jan 2017 Research programme: theranostics - NuvOx Pharma is available for licensing as of 27 Jan 2017.
  • 27 Jan 2017 Preclinical trials in Atherosclerosis (Diagnosis) in USA (unspecified route)
  • 27 Jan 2017 Preclinical trials in Atherosclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top